Shebuski R J
Upjohn Laboratories, Kalamazoo, Michigan 49001.
Toxicol Pathol. 1993;21(2):180-9. doi: 10.1177/019262339302100210.
Blood platelets play a fundamental role in hemostasis and thrombosis. The physiological role of platelets is to preserve the integrity of the cardiovascular system such that upon injury platelets are activated and serve to interrupt a potentially deleterious situation (i.e., hemorrhage). However, platelets are also involved in the pathophysiology of thrombosis in which the normal repair process is grossly exacerbated, resulting in interruption of blood flow to vital tissues. Thus, a critical balance exists between the normal function of blood platelets to preserve tissue function and a pathophysiological function in which tissue is damaged due to thrombosis and subsequent ischemia. Numerous anti-platelet agents have been developed in an attempt to interrupt the thrombotic process without severely compromising the hemostatic state of patients. This article will be devoted to a discussion of a commonly utilized anti-thrombotic agent, aspirin, as well as a class of newer, possibly more effective anti-thrombotic agents referred to collectively as fibrinogen receptor antagonists.
血小板在止血和血栓形成过程中发挥着重要作用。血小板的生理作用是维持心血管系统的完整性，以便在受伤时血小板被激活，并有助于阻止潜在的有害情况（即出血）。然而，血小板也参与血栓形成的病理生理过程，在此过程中正常的修复过程被严重加剧，导致重要组织的血流中断。因此，在血小板维持组织功能的正常功能与因血栓形成和随后的缺血导致组织受损的病理生理功能之间存在着关键的平衡。人们已经开发出许多抗血小板药物，试图在不严重损害患者止血状态的情况下中断血栓形成过程。本文将专门讨论一种常用的抗血栓药物阿司匹林，以及一类统称为纤维蛋白原受体拮抗剂的新型、可能更有效的抗血栓药物。
